Fig. 5. HOXA3 knockdown increased cisplatin resistance through EMT.

a–d CCK-8 assay of the viability of NSCLC cell lines following cisplatin treatment (0, 1.049, 2.097, 4.195, 8.389, 16.779 μM) under HOXA3 suppression for 48 h. e–f EDU assay of the proliferation of NSCLC cell lines under the IC₅₀ of cisplatin under HOXA3 suppression for 48 h. All scale bars indicate 50 μm (Green, EDU staining of dividing cells; blue, Hoechest 33342 staining of nuclei). g, h Flow cytometry detection of the apoptosis rate of NSCLC cell lines under the IC₅₀ of cisplatin under HOXA3 suppression for 48 h. i–m Western blotting of HOXA3, E-cadherin, and Vimentin levels following HOXA3 suppression for 48 h. n Western blotting of Twist1 levels following HOXA3 suppression for 48 h. (*p < 0.05, **p < 0.01, ***p < 0.001)